The presently disclosed subject matter relates to a method for selecting a compound of haploid induction. The method includes: treating a reproductive tissue of a plant with a reagent containing compounds to be tested; detecting a reactive oxygen species (ROS) level in the reproductive tissue after the treatment; and determining a compound that leads to an increase of the ROS level as the compound.

The presently disclosed subject matter relates to a method for selecting a compound of haploid induction. The method includes: treating a reproductive tissue of a plant with a reagent containing compounds to be tested; detecting a reactive oxygen species (ROS) level in the reproductive tissue after the treatment; and determining a compound that leads to an increase of the ROS level as the compound.

An object of the present invention is to provide a standard substance for quantification of PSA having a specific sugar chain that can be used in a general purpose quantification, wherein the standard substance has less unbalanced sugar chain expression patterns, can be manufactured with high reproducibility, and enables the quantification of patient's sample comprising a high concentration of PSA, and preparation method therefor, standard solution for PSA quantification, and PSA quantification method. The standard substance comprises a compound having the structure of a PSA with a sugar chain represented by any of the following formulae A to D, and is isolated and purified from a natural product, chemically or enzymatically altered from a natural product, or the compound is artificially synthesized.

An object of the present invention is to provide a standard substance for quantification of PSA having a specific sugar chain that can be used in a general purpose quantification, wherein the standard substance has less unbalanced sugar chain expression patterns, can be manufactured with high reproducibility, and enables the quantification of patient's sample comprising a high concentration of PSA, and preparation method therefor, standard solution for PSA quantification, and PSA quantification method. The standard substance comprises a compound having the structure of a PSA with a sugar chain represented by any of the following formulae A to D, and is isolated and purified from a natural product, chemically or enzymatically altered from a natural product, or the compound is artificially synthesized.

Disclosed herein are fusion proteins for use in treating an inflammatory or immune disorder and methods of use. In some examples, the fusion proteins include an anchor domain and a therapeutic polypeptide. In some examples, the fusion proteins and methods herein can be used to treat inflammatory or immune disorders.

The present invention provides a lectin-magnetic carrier coupling complex for separating glycosylated exosomes from a clinical sample. The lectin-magnetic carrier coupling complex comprises a magnetic carrier and lectins coupled to the outer side of the magnetic carrier. The lectin-magnetic carrier coupling complex provided by the present invention may rapidly, accurately, and automatically separate glycosylated exosomes from a clinical sample with a high separation efficiency; and the separated exosomes are intact in morphology without rupturing or cracking, may be directly used for liquid detection of glycosylated exosomes, or directly used for immunology-related detection, or directly used for nucleotide sequence detection and analysis after extracting nucleic acids from the exosomes.

A method for analyzing a cell surface glycan is provided, the method including bringing a glycan-binding substance labeled with a nucleic acid into contact with the cell and detecting the nucleic acid labeled to the glycan-binding substance bound to the cell, in which a kind and a quantity of the nucleic acid correspond to a kind and a quantity of the cell surface glycan.

An antiviral agent containing recombinant mistletoe lectins for treating virus infections and a medicament and/or pharmaceutical composition for treating virus infections are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain, as well as parts or fragments of the mistletoe lectin A-chain. The antiviral agent can be used for any number of virus infections, such as Herpes simplex, adenovirus, poliovirus, and poxvirus. Also, the antiviral agent can be used for skin virus warts, anogenital warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer.

An antiviral agent containing recombinant mistletoe lectins for treating virus infections and a medicament and/or pharmaceutical composition for treating virus infections are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain, as well as parts or fragments of the mistletoe lectin A-chain. The antiviral agent can be used for any number of virus infections, such as Herpes simplex, adenovirus, poliovirus, and poxvirus. Also, the antiviral agent can be used for skin virus warts, anogenital warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer.

A method of evaluating disease activity of rheumatoid arthritis with good sensitivity by a simple method, and a kit for use in the method. It provides a Jacalin-binding O-linked oligosaccharide epitope as a negative marker for diagnosing rheumatoid arthritis, and enables more accurate assessment of disease condition by more objectively determining disease activity of rheumatoid arthritis using the amount of variation of a value obtained by multiplying the amount of MMP-3 in the blood or the amount of bound MMP-3 and ABA, ACA, or ACG in the blood by the reciprocal of the amount of bound MMP-3 and Jacalin in the blood. Through the discovery that an LEL or STL-reactive sugar chain on MMP-3 in the blood is a sugar chain marker for diagnosing polymyalgia rheumatica and relapsing polychondritis, the present invention also provides a method for accurate diagnosis of polymyalgia rheumatica and relapsing polychondritis.